Dr. Hayden is the CEO of Prilenia. He is an accomplished scientist and physician. He is a Killam Professor at the University of British Columbia and Senior Scientist at the Centre for Molecular Medicine and Therapeutics. He is also a Canadian Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva from 2012-2017. He led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD in the USA.

Author of approximately 900 peer-reviewed publications, he has focused his research primarily on Huntington Disease, translational medicine, including genetics, lipoprotein disorders, predictive, personalized medicine and drug development. He also identified the first mutations underlying Lipoprotein Lipase Deficiency and developed gene therapy approaches resulting in the first approved gene therapy product (Glybera) in the world. Dr. Hayden is the recipient of numerous prestigious honors. Most recently, he was awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka MedicalCenter. He was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2015); awarded an Honorary Doctorate of Science by the Universities of Gottingen (2014) and Alberta (2009); the Luminary award by the Personalized Medicine World Conference (2014); the Diamond Jubilee Medal (2012) on behalf of HRH Queen Elizabeth II, the Killam Prize by the Canada Council of the Arts (2011), and the Canada Gairdner Wightman award (2011). Dr. Hayden is committed to empowering others. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor. For more information about Prilenia, please visit  ABOUT US | Prilenia Therapeutics